Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)

Completed

Phase 3 Results

Eligibility Criteria

INCLUSION:
Be at least 45 years old and comply with at least one of the four categories of inclusion criteria:
- Combination of atherothrombotic risk factors (2 major or 3 minor or 1 major + 2 minor risk factors among those listed below)
Major atherothrombotic risk factors
- Type I or II diabetes (under drug therapy)
- Diabetic nephropathy
- Ankle brachial index (ABI) < 0.9
- Asymptomatic carotid stenosis >= 70%
- At least one carotid plaque as evidenced by intima-media thickness (IMT)
Minor atherothrombotic risk factors
- Systolic blood pressure (SBP) >= 150 mmHg, despite appropriate therapy for at least 3 months
- Primary hypercholesterolemia
- Current smoking > 15 cigarettes per day
- Male >= 65 years
- Female >= 70 years
and/or
- Documented cerebrovascular disease (TIA or IS within 5 years) and/or
- Documented coronary artery disease (stable angina with documented multivessel coronary disease, previous documented MI, multivessel PCI or CABG within 1 year, multivessel CABG older than 1 year associated with current angina) and/or
- Documented symptomatic PAD
EXCLUSION:
- Absolute indication for the use of clopidogrel, high-dose aspirin (>162 mg), NSAIDs, or oral anti-thrombotic drugs
- Absolute contraindication to the use of clopidogrel or aspirin
- Clinical conditions likely to interfere with follow-up leading to inability to complete the trial